Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) Assets Average (2022 - 2025)

Historic Assets Average for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Q3 2025 value amounting to $278.7 million.

  • Amylyx Pharmaceuticals' Assets Average fell 438.1% to $278.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.7 million, marking a year-over-year decrease of 438.1%. This contributed to the annual value of $355.5 million for FY2024, which is 2176.45% down from last year.
  • Amylyx Pharmaceuticals' Assets Average amounted to $278.7 million in Q3 2025, which was down 438.1% from $207.1 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Assets Average's 5-year high stood at $492.0 million during Q4 2023, with a 5-year trough of $190.0 million in Q1 2022.
  • Its 4-year average for Assets Average is $317.4 million, with a median of $286.4 million in 2022.
  • As far as peak fluctuations go, Amylyx Pharmaceuticals' Assets Average surged by 12626.27% in 2023, and later tumbled by 5579.15% in 2025.
  • Quarter analysis of 4 years shows Amylyx Pharmaceuticals' Assets Average stood at $286.4 million in 2022, then surged by 71.77% to $492.0 million in 2023, then plummeted by 54.84% to $222.2 million in 2024, then grew by 25.43% to $278.7 million in 2025.
  • Its last three reported values are $278.7 million in Q3 2025, $207.1 million for Q2 2025, and $206.7 million during Q1 2025.